Pharmaceutical

IMIDomics to license TNAX’s drug candidate for IMIDs

IMIDomics has entered an agreement to license TNAX Biopharma’s IMB1001 to treat immune-mediated inflammatory diseases (IMIDs).

Sep 7, 2023 - 20:00
IMIDomics to license TNAX’s drug candidate for IMIDs
IMIDomics has entered an agreement to license TNAX Biopharma’s IMB1001 to treat immune-mediated inflammatory diseases (IMIDs).
Read the original article

Tags:

Previous Article

Veracyte and Gustave Roussy announce partnership for cancer therapies

Next Article

Novo Nordisk and Broad Institute to explore drug targets for diabetes, CMDs 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Oral solid dosage manufacturing companies, equipment and market

Oral solid dosage manufacturing companies, equipment an...

May 11, 2024

How competitive intelligence can give pharma companies an edge

How competitive intelligence can give pharma companies ...

Aug 18, 2023

STAT+: FDA chief scientist to replace Woodcock

STAT+: FDA chief scientist to replace Woodcock

Nov 29, 2023